PBYI Puma Biotechnology (PBYI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001401667
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
83
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $146.5K priced
What the filings say about PBYI
Insiders, 180 days
-$1.7M net sold
9 sellers · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$611.1K
2 notices
Puma Biotechnology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PUMA BIOTECHNOLOGY, INC. insiders sold a net $1.7M of stock across 139 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 18, 2025.
- The trade is 109.6% of the 56,700 shares held after it.
- 1 other insider sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cesano Alessandra sold about $567.0K of PBYI under a 10b5-1 plan on Sep 14, 2026, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 83 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 12, 2026.
- The trade is 9.1% of the 54,750 shares held after it.
- 1 other insider sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON TROY EDWARD sold about $45.5K of PBYI under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 83 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Jan 7, 2026.
- The trade is 0.6% of the 7,261,671 shares held after it.
- 7 other insiders sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO AUERBACH ALAN H sold about $364.1K of PBYI on Jul 6, 2026, the largest insider sale at the company on our record; 7 other insiders sold within 30 days and 83 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Jan 7, 2026.
- The trade is 4.3% of the 196,841 shares held after it.
- 7 other insiders sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks HUNT DOUGLAS M sold about $69.9K of PBYI on Jul 6, 2026; 7 other insiders sold within 30 days and 83 funds added in the latest 13F quarter.Context
- 29 earlier Form 4 trades (code P or S) here by this insider (29 sales), the last on Jan 7, 2026.
- The trade is 4.1% of the 230,637 shares held after it.
- 7 other insiders sold within 30 days.
- 83 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer NOUGUES MAXIMO F sold about $77.6K of PBYI on Jul 6, 2026; 7 other insiders sold within 30 days and 83 funds added in the latest 13F quarter.139 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.7M over 180 days
-$612.5K over 90 days · -$364.1K of it by a 10%+ holder
below 68% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
83 funds bought in last quarter
more than 61% of Pharma & Biotech
Revenue
-0.9% year over year
below 58% of Pharma & Biotech
Margin
13.6% net margin
more than 84% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.6% of the float short (float per yahoo 2026-10-26) · 14.0 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PBYI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+110.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PBYI: institutional holders (13F)
13F holdings, latest reported quarter
4,131,299 sh
$33.5M
3,804,736 sh
$30.9M
2,319,996 sh
$18.8M
1,836,213 sh
$14.9M
1,835,643 sh
$14.9M
Congress trades in PBYI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PBYI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Cesano Alessandra
Filed 2026-09-14
$565.6K
WILSON TROY EDWARD
Filed 2026-09-14
$45.5K
AUERBACH ALAN H
Filed 2026-07-06
$364.0K
HUNT DOUGLAS M
Filed 2026-07-06
$69.9K
NOUGUES MAXIMO F
Filed 2026-07-06
$77.6K
PBYI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$1.4M position · as of 2026-06-30
1.4%
NORTH SQUARE KENNEDY MICROCAP FUND
$236.8K position · as of 2026-05-31
0.7%
Hartford Multifactor Small Cap ETF
$437.4K position · as of 2026-07-31
0.7%
Small-Cap Value Fund
$2.0M position · as of 2026-06-30
0.6%
Ultra-Small Company Market Fund
$594.5K position · as of 2026-06-30
0.4%
First Trust Dow Jones Select MicroCap Index Fund
$1.1M position · as of 2026-06-30
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 2
3 active
What changed recently
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
2026-09-15 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Alan H. Auerbach
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.1M
$4.4M
$1.3M
-42%
+25%
2024
$4.0M
$2.5M
$1.3M
-70%
-7%
2023
$2.9M
$2.8M
$1.2M
-58%
-6%
2022
$2.5M
$3.2M
$982.2K
-59%
-10%
2021
$18.5M
$14.7M
$1.5M
-70%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.7M sold by insiders over 180 days, 83 funds added last quarter, $611.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
PBYI financials
Revenue growth
-0.9%
XBRL, annual
Net margin
13.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$231.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PBYI
| FY Dec 2025 | $228.4M |
| FY Dec 2024 | $230.5M |
| FY Dec 2023 | $235.6M |
| FY Dec 2022 | $228.0M |
| FY Dec 2021 | $253.2M |
| Jun 2026 | $56.5M |
| Mar 2026 | $44.8M |
| Dec 2025 | $75.5M |
| Sep 2025 | $54.5M |
| Jun 2025 | $52.4M |
| Mar 2025 | $46.0M |
| Dec 2024 | $59.1M |
| Sep 2024 | $80.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+11.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PBYI
| FY Dec 2025 | +13.6% |
| FY Dec 2024 | +13.1% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | +11.5% |
| Jun 2026 | +14.5% |
| Mar 2026 | -8.4% |
| Dec 2025 | +17.8% |
| Sep 2025 | +16.2% |
| Jun 2025 | +11.2% |
| Mar 2025 | +6.5% |
| Dec 2024 | +32.7% |
| Sep 2024 | +25.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$41.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PBYI
| FY Dec 2025 | $41.7M |
| FY Dec 2024 | $38.9M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.6M |
| Mar 2026 | $15.4M |
| Dec 2025 | $14.5M |
| Sep 2025 | $9.7M |
| Jun 2025 | $14.1M |
| Mar 2025 | $3.6M |
| Dec 2024 | $15.6M |
| Sep 2024 | $11.0M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity PBYI
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.73x |
| FY Dec 2023 | 1.86x |
| FY Dec 2022 | 4.55x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.09x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.29x |
| Jun 2025 | 0.43x |
| Mar 2025 | 0.58x |
| Dec 2024 | 0.73x |
| Sep 2024 | 1.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt PBYI
| FY Dec 2025 | 1.86x |
| FY Dec 2024 | 0.58x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | -0.16x |
| FY Dec 2021 | 0.21x |
| Jun 2026 | n/a |
| Mar 2026 | 4.75x |
| Dec 2025 | 1.86x |
| Sep 2025 | 1.28x |
| Jun 2025 | 0.99x |
| Mar 2025 | 0.56x |
| Dec 2024 | 0.58x |
| Sep 2024 | 0.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+22.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PBYI
| FY Dec 2025 | +28.0% |
| FY Dec 2024 | +41.6% |
| FY Dec 2023 | +57.5% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | n/a |
| Jun 2026 | +22.0% |
| Mar 2026 | +21.6% |
| Dec 2025 | +28.0% |
| Sep 2025 | +39.7% |
| Jun 2025 | +63.2% |
| Mar 2025 | +51.4% |
| Dec 2024 | +41.6% |
| Sep 2024 | +42.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+13.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PBYI
| FY Dec 2025 | +14.5% |
| FY Dec 2024 | +13.6% |
| FY Dec 2023 | +9.5% |
| FY Dec 2022 | +0.0% |
| FY Dec 2021 | +12.4% |
| Jun 2026 | +13.8% |
| Mar 2026 | +12.5% |
| Dec 2025 | +14.5% |
| Sep 2025 | +17.5% |
| Jun 2025 | +24.2% |
| Mar 2025 | +18.6% |
| Dec 2024 | +13.6% |
| Sep 2024 | +11.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -20%, not meaningful
Return on invested capital PBYI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +54.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | +52.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+23.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PBYI
| FY Dec 2025 | +29.6% |
| FY Dec 2024 | +24.9% |
| FY Dec 2023 | +23.7% |
| FY Dec 2022 | +18.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | +23.5% |
| Mar 2026 | +24.3% |
| Dec 2025 | +29.6% |
| Sep 2025 | +29.1% |
| Jun 2025 | +42.5% |
| Mar 2025 | +33.0% |
| Dec 2024 | +24.9% |
| Sep 2024 | +26.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
21.19x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PBYI
| FY Dec 2025 | 9.75x |
| FY Dec 2024 | 4.92x |
| FY Dec 2023 | 9.62x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 15.60x |
| Mar 2026 | 13.31x |
| Dec 2025 | 9.75x |
| Sep 2025 | 7.08x |
| Jun 2025 | 3.46x |
| Mar 2025 | 3.79x |
| Dec 2024 | 4.92x |
| Sep 2024 | 5.43x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$532.3M
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value PBYI
| FY Dec 2025 | $292.7M |
| FY Dec 2024 | $147.5M |
| FY Dec 2023 | $221.1M |
| FY Dec 2022 | $215.2M |
| FY Dec 2021 | $158.3M |
| Jun 2026 | $376.3M |
| Mar 2026 | $300.2M |
| Dec 2025 | $292.7M |
| Sep 2025 | $247.7M |
| Jun 2025 | $160.5M |
| Mar 2025 | $139.8M |
| Dec 2024 | $147.5M |
| Sep 2024 | $135.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield PBYI
| FY Dec 2025 | +13.9% |
| FY Dec 2024 | +26.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +10.0% |
| Mar 2026 | +16.5% |
| Dec 2025 | +13.9% |
| Sep 2025 | +16.0% |
| Jun 2025 | +26.0% |
| Mar 2025 | +21.2% |
| Dec 2024 | +26.0% |
| Sep 2024 | +26.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -47%, PEG needs growth
PEG, trailing PBYI
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.13x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.12x |
| Jun 2025 | 0.01x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.13x |
| Sep 2024 | 0.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $228.4M | $230.5M | $235.6M | $228.0M |
| Operating income | $37.3M | $31.0M | $32.6M | $23.7M |
| Net income | $31.1M | $30.3M | $21.6M | $2.0K |
| EPS (diluted) | 0.61 | 0.62 | 0.45 | 0.00 |
| Operating cash flow | $41.8M | $38.9M | $27.0M | -$15.8M |
| Cash | $29.6M | $69.2M | $84.6M | $76.2M |
| Long-term debt | $0 | $21.7M | $65.7M | $98.3M |
SEC XBRL, fiscal years, as known on 2026-10-27
PBYI Stock Sonar score 6/7 axes
Find similar shapesComparePBYI ranks highest on financial health (99th percentile) and profitability (92nd), and lowest on insider conviction (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PBYI filings, in plain words
Are Puma Biotechnology insiders buying or selling PBYI?
In the 180 days to 2026-10-27, Puma Biotechnology insiders were net sellers, a net $1.7M across purchases and sales reported on Form 4, by 9 sellers.
Are there planned insider sales of PBYI?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $611.1K of stock; the latest, by Cesano Alessandra, was filed 2026-09-14.
Read the full summary
In the 180 days to 2026-10-27, Puma Biotechnology insiders were net sellers of PBYI, a net $1.7M across purchases and sales reported on Form 4 by 9 sellers. 20% of the 10 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $611.1K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
